| Sep 10 |
Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Sep 5 |
Crinetics Pharmaceuticals, Inc. (CRNX): Among the Best Mid-Cap Healthcare Stocks To Buy Now
|
| Aug 29 |
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences
|
| Aug 12 |
Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Aug 12 |
Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech
|
| Aug 10 |
We Think Crinetics Pharmaceuticals (NASDAQ:CRNX) Can Afford To Drive Business Growth
|
| Aug 9 |
Crinetics Pharmaceuticals, Inc. (CRNX) Q2 2024 Earnings Call Transcript
|
| Aug 8 |
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates
|
| Aug 8 |
Crinetics Pharmaceuticals GAAP EPS of -$0.94 misses by $0.09, revenue of $0.39M misses by $0.08M
|
| Aug 8 |
Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
|
